In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of common shares plus the common shares underlying the pre-funded warrants in the offering on the same terms and conditions. All of the common shares and pre-funded warrants are being offered by Axovant. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov.

Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today provides a business and operations update during the COVID-19 pandemic. The Company has implemented a business continuity plan to protect the safety of the employees and patients and to mitigate risks of disruption to its clinical programs.

NEW YORK and BASEL, Switzerland, March 31, 2020 -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological.

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]

Top Ranked Momentum Stocks to Buy for May 5th

Axovant Gene Therapies Ltd. (AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the β-galactosidase enzyme. AXO-AAV-GM1 is an investigational gene therapy that delivers a functional copy of the GLB1 gene via an adeno-associated viral (AAV9) vector, with the goal of restoring β-galactosidase enzyme activity.

NEW YORK and BASEL, Switzerland, Feb. 10, 2020 -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided.

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx ...

Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc. together with interest, fees and other amounts due. Following the prepayment, the credit facility and loan agreement with Hercules Capital, Inc. was terminated, and all obligations, liens and security interests under the loan agreement were released, discharged and satisfied. This prepayment has no meaningful impact on our cash runway, removes prior liens by Hercules on our assets, and saves approximately $1 million in interest expense.

Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announced its collaboration with Invitae, a leading medical genetics company, in the Detect Lysosomal Storage Diseases (“Detect”) program to facilitate faster diagnoses for children with lysosomal storage disorders (“LSDs”), including GM1 gangliosidosis and GM2 gangliosidosis, also known as Tay-Sachs/Sandhoff disease. LSDs are progressive, multi-system, inherited metabolic diseases associated with premature death, and genetic testing is a crucial first step to arriving at a diagnosis.

In addition, and in lieu of common shares, Axovant is offering to certain investors pre-funded warrants to purchase 3,301,998 common shares at a purchase price of $3.74999 per pre-funded warrant, which represents the per share public offering price for the common shares, minus the $0.00001 per share exercise price of each such pre-funded warrant. All of the common shares and pre-funded warrants are being offered by Axovant.

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten.

If you're interested in Axovant Gene Therapies Ltd. (NASDAQ:AXGT), then you might want to consider its beta (a measure...

Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani, Pharm.D., SVP of Commercial Strategy and Operations, will present at the Jefferies Global Virtual Healthcare Conference. Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases.

This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.

Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its Parkinson’s program. At 12 months post-dosing, patients in the first dose cohort (4.2 x 106 TU) demonstrated an average 22-point change from baseline in motor function as assessed by the UPDRS Part III “OFF” score, which represents a 37% improvement. Previously, at 6 months post-dosing, these patients demonstrated an average 17-point change from baseline, or 29% improvement, on the same scale.

NEW YORK and BASEL, Switzerland, May 07, 2020 -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological.

Axovant (AXGT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.